Global Information
회사소개 | 문의 | 위시리스트

세계의 식물성 의약품 및 식물 유래 의약품 시장 : 인사이트, 기회 분석, 시장 점유율, 예측

Global Botanical & Plant Derived Drug Market - Technologies, Market Share and Industry Forecast to 2024

리서치사 Occams Business Research & Consulting Pvt. Ltd.
발행일 발행예정 상품 코드 457295
페이지 정보 영문
가격
US $ 5,000 ₩ 6,128,000 PDF by E-mail (Single User License)
US $ 7,000 ₩ 8,579,000 PDF by E-mail (Enterprise License)


세계의 식물성 의약품 및 식물 유래 의약품 시장 : 인사이트, 기회 분석, 시장 점유율, 예측 Global Botanical & Plant Derived Drug Market - Technologies, Market Share and Industry Forecast to 2024
발행일 : 발행예정 페이지 정보 : 영문

세계의 식물성 의약품(Botanical Drug) 및 식물 유래 의약품(Plant Derived Drug) 시장을 조사했으며, 시장 정의와 개요, 산업 구조, 규제 프레임워크, 약품 구분·용도·지역/주요 국가별 주요 동향, 시장 영향요인, 시장 규모 추이와 예측, 주요 기업과 주요 제품, 전체 시장의 경쟁 환경과 시장 점유율, 성장 기회 및 성장 전략 분석, 각종 제안 등을 정리하여 전해드립니다.

제1장 서론

  • 주요 요약
  • 시장 범위

제2장 시장 개요

  • 세계의 식물성 의약품 및 식물 유래 의약품 시장 : 추정과 발전
  • 산업 구조
  • 규제 프레임워크
  • 전체 시장 분석
  • 추정 분석
  • 전략 분석
    • 투자 및 도입 모델
    • 전방위적 산업 분석
    • Porter's Five Forces 분석
    • SEE SAW 분석
    • 가격 분석
    • 소비자 분석과 주요 구매 기준
    • 투자수익률(ROI) 분석
    • 갭 분석
  • 경쟁 분석
    • 주요 전략과 분석
    • 시장 점유율
    • 주요 기업 분석
  • 전략적 제안 및 결론
    • 투자 기회 : 지역별
    • 새로운 용도에서의 시장 기회
    • 최고 속도 성장 부문에 대한 투자 기회

제3장 시장 영향요인

  • 성장 촉진요인과 시장에 대한 영향
  • 성공 억제요인과 시장에 대한 영향
  • 시장 기회
  • 시장이 해결해야 할 과제

제4장 시장 분석과 예측 : 각종 구분별

  • 세계의 식물성 의약품 및 식물 유래 의약품 시장 분석과 예측 : 약품 구분별
    • 시장 정의와 범위
    • 의사결정 지원 데이터베이스 및 평가 방법
    • 구분별 비교 분석
    • 시장 기회 매트릭스
    • 시장 예측 : 약품별
      • 스테로이드
      • 페놀
      • 테르펜
      • 글리코시드
        • 용도
        • 도입 시나리오 및 시장 영향요인
        • 시장 평가와 예측
        • 주요 기업과 주요 제품
        • 지역 분석 및 예측
        • 결론
  • 세계의 식물성 의약품 및 식물 유래 의약품 시장 분석과 예측 : 용도별
    • 시장 정의와 범위
    • 의사결정 지원 데이터베이스 및 평가 방법
    • 구분별 비교 분석
    • 시장 기회 매트릭스
    • 시장 예측 : 용도별
      • 호르몬계 질환
      • 호흡기 질환 및 종양
      • 감염증
      • 심장혈관계/대사계 질환
      • 통증 및 중추신경계 질환
        • 용도
        • 도입 시나리오와 시장 영향요인
        • 시장 평가와 예측
        • 용도
        • 주요 기업과 주요 제품
        • 지역 분석 및 예측
        • 결론

제5장 경쟁 환경

  • 주요 전략
  • 주요 10개 기업 분석

제6장 지역 분석

  • 의사결정 지원 데이터베이스 및 평가 방법
  • 시장 세분화별 비교 분석
  • 시장 기회 매트릭스
  • 시장 분석과 예측 : 지역별
    • 북미
      • 미국
      • 캐나다
    • 유럽
      • 영국
      • 프랑스
      • 독일
      • 스페인
      • 이탈리아
      • 기타
    • 아시아태평양
      • 중국
      • 인도
      • 일본
      • 한국
      • 호주
      • 기타
    • 기타 지역
      • 라틴아메리카
      • 중동 및 아프리카

제7장 기업 개요

도표

LSH 17.03.24

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Botanical and plant derived drug market is rising with increasing prevalence of chronic diseases. According to National Institute of Health one in every five US citizen is currently living with some form of cardiovascular disease or stroke in 2016. Both cardiovascular disease and stroke brought a $350 billion burden to US economy in 2015. The burden on economy due to these disease is anticipated to increase by 5% annually. Cancer is the next most prevalent non-communicable chronic disease (NCDs) in US. National Cancer Institute estimates over 19 million people in US to be affected with some form of cancer by 2024 which has increased from 15 million in 2015. Breast cancer, lung cancer, stomach cancer, and bronchus cancer are amongst the leading forms of cancer affecting North American population. Similarly, over 86% of the total deaths in Europe resulted from NCD's according to WHO. Prevalence rate of diabetes, cancer and cardiovascular diseases are higher amongst the Western Europe and Southern European population. Europe has currently over 12% of its total population aged 60 years and above. By 2025 over 18% of European will be aged 60 years and above. With aging population prevalence rate of NCDs will increase. In next five years, prevalence rate of obesity in regions like Asia Pacific, Africa and Latin America will increase by 3% YoY. According to Asia Journal of Cancer Prevention the number of people living with cancer is estimated to reach over 15 million by 2019. Lung cancer, breast cancer, thyroid cancer, and prostate cancer are the common forms of cancer commonly found among Asia Pacific population. Along with cancer, the prevalence rate of diabetes in Asia Pacific is estimated to increase by 7% per annum. Above development endorses the growth of botanical and plant derived drug market growth from $25,400 million in 2016 to $41,722 million by 2023. The market is anticipated to grow at CAGR 6.2% during period 2016-2023.

Some of the other factors driving market include, technological advancement in drug production procedure, increasing use of plant derived drugs, and low price compared to other forms of drugs. Stringent laws and regulations, low acceptance rate for infectious diseases, lack of awareness about botanical drugs, and availability of alternative substitute are the factors impact the market growth for the forecast period 2016-2023.

Region wise global botanical and plant derived market is segmented into North America, Asia Pacific, Europe and Rest of the World (ROW). North America and Europe dominates the market in terms of revenue. Increasing awareness about botanical drugs, presence of companies manufacturing drugs from plants, sound regulatory environment and increasing prevalence rate of NCD's are the prime factors aiding market growth in North America and Europe. Asia Pacific is the fastest growing market for the forecasted period. Japan, India and China are leading market growth in Asia Pacific. Increasing healthcare expenditure, aging population, increasing prevalence of chronic diseases are the factors driving growth of botanical and plant derived drug market in Asia Pacific.

Abbott Laboratories Ltd., Bayer Healthcare Ltd., Bionova Inc., Bristol Meyers Ltd., Eli Lilly Ltd., and GSK Ltd., are amongst the pioneers in botanical and plant derived drug market. Collaborations with regional institutions, and M&A are amongst the strategies adopted by companies to grow their market share.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. MARKET SCOPE

2. MARKET OVERVIEW

  • 2.1. GLOBAL BOTANICAL & PLANT DERIVED MARKET: EVOLUTION & TRANSITION
  • 2.2. INDUSTRY STRUCTURE
  • 2.3. REGULATORY FRAMEWORK
  • 2.4. TOTAL MARKET ANALYSIS
    • 2.4.1. TOP FINDINGS
    • 2.4.2. TOP OPPORTUNITY MARKETS
    • 2.4.3. TOP COMPANIES
    • 2.4.4. TOP COMPETITIVE STRATEGIES
  • 2.5. ESTIMATION ANALYSIS
  • 2.6. STRATEGIC ANALYSIS
    • 2.6.1. INVESTMENT VS. ADOPTION MODEL
    • 2.6.2. 360 DEGREE INDUSTRY ANALYSIS
    • 2.6.3. PORTERS 5 FORCE MODEL
    • 2.6.4. SEE-SAW ANALYSIS
    • 2.6.5. PRICING ANALYSIS
    • 2.6.6. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
    • 2.6.7. ROI ANALYSIS
    • 2.6.8. GAP ANALYSIS
  • 2.7. COMPETITIVE ANALYSIS
    • 2.7.1. KEY STRATEGIES AND ANALYSIS
    • 2.7.2. MARKET SHARE
    • 2.7.3. TOP COMPANY ANALYSIS
  • 2.8. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
    • 2.8.1. INVESTMENT OPPORTUNITIES BY REGIONS
    • 2.8.2. OPPORTUNITIES IN EMERGING APPLICATIONS
    • 2.8.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS& MARKET IMPACT
    • 3.1.1. INCREASING PREVALENCE OF CHRONIC DISEASES
    • 3.1.2. TECHNOLOGICAL ADVANCEMENT IN PRODUCTION PROCEDURE
    • 3.1.3. COMPARATIVELY LOW PRICE
    • 3.1.4. INCREASE IN USE OF PLANT DERIVED DRUGS
  • 3.2. MARKET RESTRAINTS & MARKET IMPACT
    • 3.2.1. STRINGENT GOVERNMENT LAWS & REGULATIONS
    • 3.2.2. LOW ACCEPTANCE RATE FOR LETHAL DISEASES
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. ENHANCED APPLICATIONS
    • 3.3.2. INCREASING APPROVAL BY FDA
  • 3.4. MARKET CHALLENGES
    • 3.4.1. LACK OF AWARENESS ABOUT BOTANICAL DRUGS
    • 3.4.2. AVAILABILITY OF ALTERNATIVE SUBSTITUTES

4. MARKET SEGMENTATION

  • 4.1. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY DRUG TYPE
    • 4.1.1. MARKET DEFINITION AND SCOPE
    • 4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.1.4. OPPORTUNITY MATRIX
    • 4.1.5. MARKET SEGMENTATION
      • 4.1.5.1. STEROIDS
        • 4.1.5.1.1. APPLICATIONS
        • 4.1.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.1.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.1.5. KEY CONCLUSIONS
      • 4.1.5.2. PHENOLS
        • 4.1.5.2.1. APPLICATIONS
        • 4.1.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.1.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.2.5. KEY CONCLUSIONS
      • 4.1.5.3. TERPENES
        • 4.1.5.3.1. APPLICATIONS
        • 4.1.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.1.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.3.5. KEY CONCLUSIONS
      • 4.1.5.4. GLYCOSIDES
        • 4.1.5.4.1. APPLICATIONS
        • 4.1.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.1.5.4.4. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.4.5. KEY CONCLUSIONS
  • 4.2. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY APPLICATION
    • 4.2.1. MARKET DEFINITION AND SCOPE
    • 4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.2.4. OPPORTUNITY MATRIX
    • 4.2.5. MARKET SEGMENTATION
      • 4.2.5.1. HORMONE DISEASES
        • 4.2.5.1.1. APPLICATIONS
        • 4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.1.5. KEY CONCLUSIONS
      • 4.2.5.2. RESPIRATORY & ONCOLOGY DISEASE
        • 4.2.5.2.1. APPLICATIONS
        • 4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.2.5. KEY CONCLUSIONS
      • 4.2.5.3. INFECTIOUS DISEASE
        • 4.2.5.3.1. APPLICATIONS
        • 4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.3.5. KEY CONCLUSIONS
      • 4.2.5.4. CARDIOVASCULAR & METABOLIC DISEASE
        • 4.2.5.4.1. APPLICATIONS
        • 4.2.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.4.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.4.5. KEY CONCLUSIONS
      • 4.2.5.5. PAIN & CNS DISORDER
        • 4.2.5.5.1. APPLICATIONS
        • 4.2.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.5.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.5.5. KEY CONCLUSIONS

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
    • 5.1.1. LIST OF M&A
    • 5.1.2. LIST OF JV
    • 5.1.3. LIST OF PRODUCT LAUNCHES
    • 5.1.4. LIST OF PARTNERSHIP
  • 5.2. TOP 10 COMPANY ANALYSIS - DASHBOARD

6. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY REGION

  • 6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 6.3. OPPORTUNITY MATRIX
  • 6.4. GEOGRAPHIC SEGMENTATION
    • 6.4.1. NORTH AMERICA
      • 6.4.1.1. INDUSTRY APPLICATION ANALYSIS
      • 6.4.1.2. TOP COUNTRY ANALYSIS
        • 6.4.1.2.1. U.S.
          • 6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.1.2.1.3. KEY CONCLUSIONS
        • 6.4.1.2.2. CANADA
          • 6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.1.2.2.3. KEY CONCLUSIONS
    • 6.4.2. EUROPE
      • 6.4.2.1. INDUSTRY APPLICATION ANALYSIS
      • 6.4.2.2. TOP COUNTRY ANALYSIS
        • 6.4.2.2.1. UK
          • 6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.1.3. KEY CONCLUSIONS
        • 6.4.2.2.2. FRANCE
          • 6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.2.3. KEY CONCLUSIONS
        • 6.4.2.2.3. GERMANY
          • 6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.3.3. KEY CONCLUSIONS
        • 6.4.2.2.4. SPAIN
          • 6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.4.3. KEY CONCLUSIONS
        • 6.4.2.2.5. ITALY
          • 6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.5.3. KEY CONCLUSIONS
        • 6.4.2.2.6. REST OF EUROPE
          • 6.4.2.2.6.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.6.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.6.3. KEY CONCLUSIONS
    • 6.4.3. ASIA PACIFIC
      • 6.4.3.1. INDUSTRY APPLICATION ANALYSIS
      • 6.4.3.2. TOP COUNTRY ANALYSIS
        • 6.4.3.2.1. CHINA
          • 6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.1.3. KEY CONCLUSIONS
        • 6.4.3.2.2. INDIA
          • 6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.2.3. KEY CONCLUSIONS
        • 6.4.3.2.3. JAPAN
          • 6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.3.3. KEY CONCLUSIONS
        • 6.4.3.2.4. SOUTH KOREA
          • 6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.4.3. KEY CONCLUSIONS
        • 6.4.3.2.5. AUSTRALIA
          • 6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.5.3. KEY CONCLUSIONS
        • 6.4.3.2.6. REST OF ASIA PACIFIC
          • 6.4.3.2.6.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.6.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.6.3. KEY CONCLUSIONS
    • 6.4.4. ROW
      • 6.4.4.1. INDUSTRY APPLICATION ANALYSIS
      • 6.4.4.2. TOP COUNTRY ANALYSIS
        • 6.4.4.2.1. LATIN AMERICA
          • 6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.4.2.1.3. KEY CONCLUSIONS
        • 6.4.4.2.2. MIDDLE EAST & AFRICA
          • 6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.4.2.2.3. KEY CONCLUSIONS

7. COMPANY PROFILES

  • 7.1. ABBOTT LABORATORIES
    • 7.1.1. OVERVIEW
    • 7.1.2. PRODUCT PORTFOLIO
    • 7.1.3. KEY INNOVATION SECTOR
    • 7.1.4. STRATEGIC INITIATIVES
    • 7.1.5. SCOT ANALYSIS
  • 7.2. BAYER HEALTHCARE
    • 7.2.1. OVERVIEW
    • 7.2.2. PRODUCT PORTFOLIO
    • 7.2.3. KEY INNOVATION SECTOR
    • 7.2.4. STRATEGIC INITIATIVES
    • 7.2.5. SCOT ANALYSIS
  • 7.3. BIONOVA
    • 7.3.1. OVERVIEW
    • 7.3.2. PRODUCT PORTFOLIO
    • 7.3.3. KEY INNOVATION SECTOR
    • 7.3.4. STRATEGIC INITIATIVES
    • 7.3.5. SCOT ANALYSIS
  • 7.4. BRISTOL MEYERS
    • 7.4.1. OVERVIEW
    • 7.4.2. PRODUCT PORTFOLIO
    • 7.4.3. KEY INNOVATION SECTOR
    • 7.4.4. STRATEGIC INITIATIVES
    • 7.4.5. SCOT ANALYSIS
  • 7.5. ELI LILLY
    • 7.5.1. OVERVIEW
    • 7.5.2. PRODUCT PORTFOLIO
    • 7.5.3. KEY INNOVATION SECTOR
    • 7.5.4. STRATEGIC INITIATIVES
    • 7.5.5. SCOT ANALYSIS
  • 7.6. GSK LTD
    • 7.6.1. OVERVIEW
    • 7.6.2. PRODUCT PORTFOLIO
    • 7.6.3. KEY INNOVATION SECTOR
    • 7.6.4. STRATEGIC INITIATIVES
    • 7.6.5. SCOT ANALYSIS
  • 7.7. JHONSON & JHONSON
    • 7.7.1. OVERVIEW
    • 7.7.2. PRODUCT PORTFOLIO
    • 7.7.3. KEY INNOVATION SECTOR
    • 7.7.4. STRATEGIC INITIATIVES
    • 7.7.5. SCOT ANALYSIS
  • 7.8. LUPIN LTD
    • 7.8.1. OVERVIEW
    • 7.8.2. PRODUCT PORTFOLIO
    • 7.8.3. KEY INNOVATION SECTOR
    • 7.8.4. STRATEGIC INITIATIVES
    • 7.8.5. SCOT ANALYSIS
  • 7.9. MEDIGENE
    • 7.9.1. OVERVIEW
    • 7.9.2. PRODUCT PORTFOLIO
    • 7.9.3. KEY INNOVATION SECTOR
    • 7.9.4. STRATEGIC INITIATIVES
    • 7.9.5. SCOT ANALYSIS
  • 7.10. NOVARTIS INTERNATIONAL
    • 7.10.1. OVERVIEW
    • 7.10.2. PRODUCT PORTFOLIO
    • 7.10.3. KEY INNOVATION SECTOR
    • 7.10.4. STRATEGIC INITIATIVES
    • 7.10.5. SCOT ANALYSIS
  • 7.11. PFIZER
    • 7.11.1. OVERVIEW
    • 7.11.2. PRODUCT PORTFOLIO
    • 7.11.3. KEY INNOVATION SECTOR
    • 7.11.4. STRATEGIC INITIATIVES
    • 7.11.5. SCOT ANALYSIS
  • 7.12. RANBAXY LABS
    • 7.12.1. OVERVIEW
    • 7.12.2. PRODUCT PORTFOLIO
    • 7.12.3. KEY INNOVATION SECTOR
    • 7.12.4. STRATEGIC INITIATIVES
    • 7.12.5. SCOT ANALYSIS
  • 7.13. GLENMARK PHARMACEUTICALS LTD
    • 7.13.1. OVERVIEW
    • 7.13.2. PRODUCT PORTFOLIO
    • 7.13.3. KEY INNOVATION SECTOR
    • 7.13.4. STRATEGIC INITIATIVES
    • 7.13.5. SCOT ANALYSIS
  • 7.14. TASLY PHARMACEUTICALS INC
    • 7.14.1. OVERVIEW
    • 7.14.2. PRODUCT PORTFOLIO
    • 7.14.3. KEY INNOVATION SECTOR
    • 7.14.4. STRATEGIC INITIATIVES
    • 7.14.5. SCOT ANALYSIS
  • 7.15. PIRAMAL PHYTOCARE LTD
    • 7.15.1. OVERVIEW
    • 7.15.2. PRODUCT PORTFOLIO
    • 7.15.3. KEY INNOVATION SECTOR
    • 7.15.4. STRATEGIC INITIATIVES
    • 7.15.5. SCOT ANALYSIS

LIST OF TABLES

  • 1. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY DRUG TYPE 2014-2023 ($ MILLION)
  • 2. GLOBAL STEROID DRUG TYPE BOTANICAL & PLANT DERIVED MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 3. GLOBAL PHENOL DRUG TYPE BOTANICAL & PLANT DERIVED MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 4. GLOBAL TERPENES DRUG TYPE MARKET BY PRODUCT 2014-2023 ($ MILLION)
  • 5. GLOBAL GLYCOSIDES DRUG TYPE MARKET BY PRODUCT 2014-2023 ($ MILLION)
  • 6. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY APPLICATION 2014-2023 ($ MILLION)
  • 7. GLOBAL HORMONE DISEASE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 8. GLOBAL PAIN & CNS DISORDER BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 9. NORTH AMERICA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 10. EUROPE BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 11. ASIA PACIFIC BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 12. REST OF THE WORLD BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY STEROID DRUG TYPE 2014-2023 ($ MILLION)
  • 2. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY PHENOL DRUG TYPE 2014-2023 ($ MILLION)
  • 3. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY TERPENES DRUG TYPE 2014-2023 ($ MILLION)
  • 4. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY GLYCOSIDE DRUG TYPE 2014-2023 ($ MILLION)
  • 5. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY SOFT-TUBE FILLING AND SEALING MACHINES 2014-2023 ($ MILLION)
  • 6. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY HORMONE DISORDER 2014-2023 ($ MILLION)
  • 7. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY PAIN & CNS DISORDER 2014-2023 ($ MILLION)
  • 8. UNITED STATES (U.S.) BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 9. CANADA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 10. UNITED KINGDOM (UK) BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 11. FRANCE BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 12. GERMANY BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 13. SPAIN BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 14. ITALY BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 15. ROE BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 16. INDIA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 17. CHINA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 18. JAPAN BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 19. KOREA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 20. AUSTRALIA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 21. ROW APAC BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 22. LATIN AMERICA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
  • 23. MENA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
Back to Top
전화 문의
F A Q